Abstract
Cis-diammine dichloro platinum (II) (CDDP), is a highly potent antineoplastic agent that is used in the treatment of ovarian cancer. However, the clinical use of CDDP is restricted by its severe side effects. In order to reduce these side effects and to enhance its therapeutic efficacy, we developed specific immunoconjugates consisting of the murine monoclonal antibody OC125 and CDDP, using diethylene triamine pentaacetic acid (DTPA) as a linker.
The coupling efficiencies of the different preparations synthesized, varied between 1.10±0.42 and 2.65±1.60 mol of CDDP per mol of antibody protein. Despite the chemical modification of the antibody molecule, specific binding activity of the OC125-CDDP conjugates toward the CA125 antigen was maintained as was demonstrated by means of immunohisto-/cytochemical staining of frozen sections of ovarian cancer tissue, amniotic epithelium, and the CA125 positive ovarian cancer cell line NIH:OVCAR 3.
The antiproliferative activity of the immunoconjugates was tested against the human ovarian cancer cell lines NIH:OVCAR3 and SKOV 3, applying a kinetic crystal violet microassay.
Despite the promising results obtained with the specific immuno-staining of the target cells, no significant antiproliferative activity of our immunoconjugates against the cell lines tested was observed.
One possible explanation for the lack of antitumor activity could be the fact that CA125 is released in large amounts by the NIH:OVCAR 3 cells. This may have prevented an efficient immunotargeting of the cancer cells by the formation of soluble immune complexes.
Similar content being viewed by others
References
Ehrlich, P. (1990)Proc. Roy. Soc. (London) 66, 424.
Koehler, G. and Milstein, C. (1975)Nature (London) 256, 495.
Reckel, R. (1989)Adv. Clin. Chem. 27, 355.
Bast, R. C., Feeny, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. (1981)J. Clin. Invest. 68, 1331.
Jäger, W., Feistel, H., Paterok, E. M., Ronay, G., Tulusan, A. H., Wolf, F., et al. (1990)Br. J. Cancer 62 (Suppl. X), 18.
Beck, E., Jäger, W., Wildt, L., and Lang, N. (1991)Recent Results in Tumor Diagnosis and Therapy (Klapdor, R., ed.), Zuckschwerdt Verlag, Munich, pp. 531–536.
Hnatowich, J. J., Childs, R. L., Lateigne, D., and Najafi, A. (1983)J. Immunol. Meth. 65, 147.
Koch, B., Baum, W., Beck, E., Eger, G., Rohwer, P., Kalden, J. R., et al. (1991)Antibody Immunoconj. Radiopharma. 4, 121.
Bernhardt, G., Reile, H., Birnböck, H., Spruss, T., and Schönenberger, H. (1992)J. Cancer Res. Clin. Oncol. 118, 35.
Bernhardt, G., Müller, R., Gust, R., Reile, H., Keller, C., Spruss, T., et al. (1991)Arch. Pharm. 324.
Bradford, M. M. (1978)Anal. Biochem. 72, 248.
Reed, E. and Kohn, R. K. (1990)Cancer Chemotheraphy: Principles and Practice (Chabner, B. A. and Collins, J. M., ed.), Lippincott, Philadelphia, p. 465.
Gallego, J., Rice, M. R., and Baldwin, R. W. (1984)Int. J. Cancer 33, 737.
Sweet, F., Rosnik, L. O., Sommers, G. M., and Collins, J. L. (1989)Gynecol. Oncol. 34, 505.
Ogden, J. R., Leung, K., Kunda, S. A., Telander, M. W., Avner, B. P., Liao, S. K., et al. (1989)Mol. Biother. 1, 170.
Mohamed, G., Kuzmanoff, K. M., Stastny, J. J., and dasGupta, T. K. (1992)Anticancer Res. 12, 529.
Embleton, M. J., Rowland, G. F., Simmonds, R. G., Jacobs, E., Marsden, C. H., and Baldwin, R. W. (1983)Br. J. Cancer 47, 43.
Spearman, M. E., Goodwin, R. M., Apelgren, L. D., and Bumol, T. F. (1987)J. Pharmacol. Exp. Ther. 241, 695.
Garnett, M. C., Embleton, M. J., Jacobs, E., and Baldwin, R. W. (1983)Int. J. Cancer 31, 661.
Umemoto, N., Kato, Y., Endo, N., Takeda, Y., and Hara, T. (1989)Int. J. Cancer 43, 667.
Hurwitz, E., Hashia, R., and Wilchek, M. (1982)J. Natl. Cancer Inst. 69, 47.
Schechter, B., Pawzner, R., Aron, R., Haimovich, J., and Wilchek, M. (1987)Cancer Immunol. Immunother. 25, 225.
Beck, E., Hofmann, M., Kiesewetter, F., Jäger, W., Wildt, L., and Lang, N. (1992)Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties (Klapdor, R., ed.), W. Zuckscherdt Verlag GmbH, Munich, pp. 117–121.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beck, E., Hofmann, M., Bernhardt, G. et al. In vitro activity of immunoconjugates between cisplatin and an anti-CA125 monoclonal antibody on ovarian cancer cell lines. Cell Biophysics 24, 163–173 (1994). https://doi.org/10.1007/BF02789227
Issue Date:
DOI: https://doi.org/10.1007/BF02789227